A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

Inclusion Criteria

• •Inclusion Criterion:
• •1. Provide a urine sample that tests negative for opioids, methadone, buprenorphine, oxycodone, amphetamine, cocaine, and benzodiazepines
• •2. Negative ethanol breath test (0.000)
• •3. Aged 21-50
• •4. Deemed medically eligible to take hydromorphone
• •Exclusion Criterion:
• •1. Answer "yes" to question 1 of the Brief Pain Inventory (89) to assess the presence of chronic pain.
• •2. Current use of opioids or other medications for pain
• •3. Meet DSM-5 criteria for current or lifetime alcohol or drug use disorder (excluding nicotine)
• •4. Self-report any illicit drug use in the past 7 days
• •5. Self-report opioid use \>5 days in the past 30
• •6. Evidence of opioid physical dependence at screening or following 1st residential overnight (following confirmed opioid abstinence)
• •7. Allergy to hydromorphone or other opioid agonists
• •8. Experience an adverse event that warrants opioid antagonist treatment following 1st hydromorphone dose.
• •9. If female, not be pregnant or breastfeeding
• •10. Presence of any clinically significant medical (e.g., chronic renal insufficiency, history of myocardial infarction, seizure disorder) and/or psychiatric illness (e.g., schizophrenia, bipolar disorder) that may interfere with study participation.
• •11. BMI \>30 (obese category)